Larazotide Dosage Chart & Schedule
An orally administered octapeptide studied as a 'tight-junction regulator' for reducing intestinal permeability, most notably in celiac-disease research.
Larazotide is an orally administered tight-junction regulator studied mainly in celiac disease, acting locally in the gut with minimal systemic absorption. Trials used 0.5 mg (500 mcg) by mouth before meals; a Phase 3 trial was halted for futility, and it is not approved.
Figures describe how Larazotide is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- 3x daily (before meals)
- Weekly total
- ~10.5 mg/week
- Cycle
- Continuous with meals in trials
Celiac trials found 0.5 mg most effective; higher doses were not better, so a single dose is shown.
Acts locally in the gut
- A poorly absorbed zonulin antagonist that works in the gut lumen with minimal systemic exposure.
- Proposed to promote tight-junction assembly and reduce intestinal permeability.
Investigational
- Celiac-disease Phase 3 trial was halted for futility; not approved.
- Higher doses (studied up to a few milligrams) did not outperform 0.5 mg.
Ready to run this protocol?
Dosing is only as good as the vial. Research-grade peptides are third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
Handling & storage
- Administered orally as 0.5 mg capsules; it is not reconstituted for injection.
- Trials took it shortly before meals, since it acts locally in response to a meal-related trigger.
- Store capsules in a cool, dry, sealed container.
Larazotide dosing FAQ
Is larazotide injected?
No. It is taken orally and acts locally in the gut lumen; it is poorly absorbed by design.
What dose was used in trials?
Celiac-disease trials used 0.5 mg (500 mcg) orally before meals, typically up to three times daily.
Why before meals?
It targets meal- and gluten-related tight-junction disruption, so dosing is timed just before eating.
Were higher doses better?
No. Trials found 0.5 mg most effective, and a Phase 3 trial was ultimately halted for futility.
Sources
Categories: Immune & Gut · Status: Investigational. This page is educational and for laboratory research use only; it is not medical advice.